Abstract: Provided are use of a drug conjugate in treatment of a tumor disease and a method thereof. Specifically provided are use of a bioactive conjugate as shown in formula (I) for treating HR+/Her2? breast cancer and a method thereof. Formula (I):{D-[L1-(L2)m1-(L3)m2-(L4)m3-E]}?-A.

Abstract: The present application provides a preparation method for a nitrogen-containing fused ring compound having anti-tumor activity. According to the method, a target product can be efficiently obtained under relatively mild reaction conditions, and upon comparison with the original processes, the yield rate is remarkably improved, and the material cost is greatly reduced, thereby better facilitating process scale-up.

Abstract: The present application relates to the field of medicines, and in particular to an antibody-drug conjugate of a glucocorticoid receptor agonist. Specifically, the present application provides a glucocorticoid receptor agonist, which has good agonistic activity. The present application further provides a drug-linker compound for coupling, wherein the drug is a glucocorticoid receptor agonist. The present application further provides an antibody-drug conjugate prepared by coupling the drug-linker compound and the antibody, wherein the antibody-drug conjugate has good drug coupling uniformity, and has an excellent treatment effect on inflammatory diseases such as rheumatoid arthritis. The present application further provides a preparation method for the glucocorticoid receptor agonist and the antibody-drug conjugate thereof, and uses of the glucocorticoid receptor agonist and the antibody-drug conjugate thereof in the field of medicines.

Abstract: The present application provides a method for preparing a drug-linker conjugate. Specifically, the present application provides a method for preparing compound IM2, which comprises the following steps: adding compound SM1 to a mixed solution of triphosgene and 4-dimethylaminopyridine to obtain an intermediate solution; adding compound SM2 to the intermediate solution, stirring the mixture, thereby obtaining compound IM2. The stability, practicality and scalability of the process are improved by optimizing the preparation process of IM2 and using a normal chromatography purification method that is easily scalable.

Abstract: The present invention belongs to the field of pharmaceuticals, and particularly relates to a tricyclic compound, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, a method for preparing same, a pharmaceutical composition comprising same, and uses thereof.

Abstract: The present disclosure relates to an antibody-drug conjugate (ADC) for treating CDH3-positive cancer. The ADCs have a CDH3 antibody and a drug-linker molecule conjugated to the antibody. The ADC of the present disclosure has a better drug-antibody conjugation ratio and a good, targeted killing effect on CDH3-positive cancer. Also provided is a preparation method of the antibody-drug conjugate and use thereof in the treatment of the CDH3-positive cancer.

Abstract: The present application relates to an antibody-drug conjugate and a method for preparation and use thereof, and specifically relates to an antibody-drug conjugate for treating CEACAM5-positive cancer, including an anti-CEACAM5 antibody, and drug-linker molecules conjugated to the antibody. In some embodiments, the antibody is humanized. In some embodiments, the antibody has excellent binding activity to CEACAM5-positive cells, and can efficiently deliver drugs to CEACAM5-positive cells. In some embodiments, the drug includes a DNA topoisomerase inhibitor. The antibody-drug conjugate of the present application has a better drug-antibody conjugation ratio, and has a good targeted killing effect on certain cancers.

Abstract: The present invention belongs to the technical field of biomedicine, and relates to a method for treating cancer by using an antibody-drug conjugate. In particular, the present invention relates to a use of an antibody drug conjugate represented by formula (I) and a pharmaceutically acceptable salt, a stereoisomer or a metabolite thereof, or a solvate of the foregoing in the manufacture of a medicament for preventing and/or treating a HER2-expressing, amplified or mutated cancer, wherein A is a group obtained by removing n amino groups from an antibody against HER2 or an active fragment or variant thereof; preferably, A is trastuzumab or a group obtained by removing n amino groups from Pertuzumab; n is selected from 1-10, such as 2-10 or 2-8; and preferably, n is an integer of 1, 2, 3, 4, 5, 6, 7 or 8.

Abstract: Disclosed in the present invention is a compound and the use thereof in preparation of BCL-XL inhibitor, belong to the field of pharmacy. The structure of the compound provided by the present invention is represented in Formula I. The compound can effectively bind to BCL-XL protein, thereby further inhibiting activity of the BCL-XL protein. The compound an be used for preparing a BCL-XL inhibitor and drugs for preventing and/or treating diseases related to the BCL-XL protein activity (such as cancer and autoimmune diseases, etc.), and has broad prospect in clinical application. The compound has good pharmacological characteristics, good stability, high drugability. In assition, the compound has simple preparation method, high yield and low cost, and thus is suitable for industrial production.

Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition comprising same, and a preparation method for the heterocyclic compound, and further relates to a use of the compound in the preparation of a drug for treating thromboembolic diseases.

Abstract: The present invention relates to the field of biomedicine, and in particular, the present invention relates to an antibody or antigen-binding fragment thereof which specifically binds to MSLN, and a chimeric antigen receptor (CAR) comprising said antibody or antigen-binding fragment thereof. The present invention also relates to modified immune cells expressing said CAR, or co-expressing said CAR and additional bioactive molecules (e.g. PD-1 antibody and/or mIL-15), and a method for preparing said modified immune cells.

Abstract: The present invention belongs to the field of pharmaceuticals, and particularly relates to a tricyclic compound, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, a method for preparing same, a pharmaceutical composition comprising same, and uses thereof.

Abstract: Provided are an anti-Nectin-4 antibody or antigen-binding fragment thereof, an antibody conjugate comprising the same, and use thereof in the manufacture of a medicament, particularly in the manufacture of a medicament for treating and/or preventing cancer.

Abstract: Provided are an antibody-drug conjugate, a pharmaceutical composition thereof and use thereof. Particularly, provided are an antibody-drug conjugate of formula (I), a drug-linker for preparing the antibody-drug conjugate, and use of the antibody-drug conjugate in combating tumors.

Abstract: Antibody-drug conjugates (ADC) useful for preventing, treating, and/or acting as an adjuvant in treating c-MET and/or EGFR-related diseases are disclosed. The ADCs comprise a bispecific antibody or antigen-binding fragment thereof comprising an arm specific for binding to EGFR and an arm specific for binding to c-MET conjugated to a cytotoxic drug.

Abstract: A compound having a BCL-XL protein degradation function as shown in Formula I and a use thereof in preparation of a drug for diseases associated with BCL-XL activity.

Abstract: A combination of an anti-TROP-2 antibody-drug conjugate and anti-PD-L1 antibody or other chemotherapeutic drugs such as Carboplatin or Cisplatin, and an application of the combination in the preparation of drugs for preventing and/or treating tumor diseases, wherein the anti-TROP-2 antibody may be Sacituzumab.

Abstract: Provided are an anti-Nectin-4 antibody or antigen-binding fragment thereof, an antibody conjugate comprising the same, and use thereof in the manufacture of a medicament, particularly in the manufacture of a medicament for treating and/or preventing cancer.

Abstract: The present application relates to a method for improving the product quality of an antibody-drug conjugate. The method comprises: conjugating a drug to be conjugated to an antibody to obtain an antibody-drug conjugate; and purifying the antibody-drug conjugate: a regulation solution is added to the antibody-drug conjugate, column chromatography flowthrough is performed to collect a product, and the product is further subjected to ultrafiltration and/or diafiltration concentration to obtain an antibody-drug conjugate with improved product quality. The obtained antibody-drug conjugate has high purity, a uniform DAR, no solvent residue, and stable quality. Moreover, the pretreatment of the antibody does not involve steps such as ultrafiltration and diafiltration, which simplifies antibody purification and reduces production costs.

Abstract: The present disclosure relates to methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I): wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.